https://scholars.lib.ntu.edu.tw/handle/123456789/552853
DC 欄位 | 值 | 語言 |
---|---|---|
dc.contributor.author | Yun-Chieh Sung | en_US |
dc.contributor.author | Ya-Chi Liu | en_US |
dc.contributor.author | Po-Han Chao | en_US |
dc.contributor.author | Chih-Chun Chang | en_US |
dc.contributor.author | Pei-Ru Jin | en_US |
dc.contributor.author | Ts-Ting Lin | en_US |
dc.contributor.author | Ja-An Lin | en_US |
dc.contributor.author | HUI-TENG CHENG | en_US |
dc.contributor.author | Jane Wang | en_US |
dc.contributor.author | Charles P. Lai | en_US |
dc.contributor.author | Ling-Hsuan Chen | en_US |
dc.contributor.author | Anthony Y. Wu | en_US |
dc.contributor.author | Ting-Lun Ho | en_US |
dc.contributor.author | Tsaiyu Chiang | en_US |
dc.contributor.author | Dong-Yu Gao | en_US |
dc.contributor.author | Dan G. Duda | en_US |
dc.contributor.author | Yunching Chen | en_US |
dc.date.accessioned | 2021-03-15T08:46:51Z | - |
dc.date.available | 2021-03-15T08:46:51Z | - |
dc.date.issued | 2018 | - |
dc.identifier.issn | 1838-7640 | - |
dc.identifier.uri | https://www.scopus.com/inward/record.uri?eid=2-s2.0-85040005273&doi=10.7150%2fthno.21168&partnerID=40&md5=408a4652cfc545b6f9a8e0fd2d21fb2d | - |
dc.identifier.uri | https://scholars.lib.ntu.edu.tw/handle/123456789/552853 | - |
dc.description.abstract | Liver damage and fibrosis are precursors of hepatocellular carcinoma (HCC). In HCC patients, sorafenib-a multikinase inhibitor drug-has been reported to exert anti-fibrotic activity. However, incomplete inhibition of RAF activity by sorafenib may also induce paradoxical activation of the mitogen-activated protein kinase (MAPK) pathway in malignant cells. The consequence of this effect in non-malignant disease (hepatic fibrosis) remains unknown. This study aimed to examine the effects of sorafenib on activated hepatic stellate cells (HSCs), and develop effective therapeutic approaches to treat liver fibrosis and prevent cancer development. Methods: We first examined the effects of sorafenib in combination with MEK inhibitors on fibrosis pathogenesis in vitro and in vivo. To improve the bioavailability and absorption by activated HSCs, we developed CXCR4-targeted nanoparticles (NPs) to co-deliver sorafenib and a MEK inhibitor to mice with liver damage. Results: We found that sorafenib induced MAPK activation in HSCs, and promoted their myofibroblast differentiation. Combining sorafenib with a MEK inhibitor suppressed both paradoxical MAPK activation and HSC activation in vitro, and alleviated liver fibrosis in a CCl4-induced murine model of liver damage. Furthermore, treatment with sorafenib/MEK inhibitor-loaded CXCR4-targeted NPs significantly suppressed hepatic fibrosis progression and further prevented fibrosis-associated HCC development and liver metastasis. Conclusions: Our results show that combined delivery of sorafenib and a MEK inhibitor via CXCR4-targeted NPs can prevent activation of ERK in activated HSCs and has anti-fibrotic effects in the CCl4-induced murine model. Targeting HSCs represents a promising strategy to prevent the development and progression of fibrosis-associated HCC. ? Ivyspring International Publisher. | - |
dc.publisher | Ivyspring International Publisher | - |
dc.relation.ispartof | Theranostics | en_US |
dc.subject.classification | [SDGs]SDG3 | - |
dc.subject.other | chemokine receptor CXCR4; mitogen activated protein kinase; mitogen activated protein kinase kinase inhibitor; nanoparticle; selumetinib; sorafenib; chemokine receptor CXCR4; chloroform; CXCR4 protein, mouse; nanoparticle; protein kinase inhibitor; sorafenib; animal experiment; animal model; animal tissue; antifibrotic activity; Article; cancer prevention; cell activation; cell differentiation; cell survival; cell viability; controlled study; drug activity; drug effect; drug mechanism; enzyme activation; hepatic stellate cell; in vitro study; in vivo study; liver carcinogenesis; liver cell carcinoma; liver fibrosis; liver injury; liver metastasis; male; mouse; myofibroblast; nonhuman; tumor volume; animal; antagonists and inhibitors; chemically induced; disease model; liver cell carcinoma; liver cirrhosis; liver tumor; metabolism; physiology; treatment outcome; Animals; Carcinoma, Hepatocellular; Chloroform; Disease Models, Animal; Hepatic Stellate Cells; Liver Cirrhosis; Liver Neoplasms; Mice; Nanoparticles; Protein Kinase Inhibitors; Receptors, CXCR4; Sorafenib; Treatment Outcome | - |
dc.title | Combined delivery of sorafenib and a MEK inhibitor using CXCR4-targeted nanoparticles reduces hepatic fibrosis and prevents tumor development | en_US |
dc.type | journal article | en |
dc.identifier.doi | 10.7150/thno.21168 | - |
dc.identifier.pmid | 29463989 | - |
dc.identifier.scopus | 2-s2.0-85040005273 | - |
dc.relation.pages | 894-905 | - |
dc.relation.journalvolume | 8 | - |
dc.relation.journalissue | 4 | - |
item.cerifentitytype | Publications | - |
item.fulltext | no fulltext | - |
item.openairecristype | http://purl.org/coar/resource_type/c_6501 | - |
item.openairetype | journal article | - |
item.grantfulltext | none | - |
crisitem.author.dept | Internal Medicine | - |
crisitem.author.dept | Internal Medicine-NTUHHC | - |
crisitem.author.orcid | 0000-0003-1544-7473 | - |
crisitem.author.parentorg | College of Medicine | - |
crisitem.author.parentorg | NTU Hsin-Chu Hospital | - |
顯示於: | 醫學系 |
在 IR 系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。